Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Xoma Royalty Depository Shares Series B XOMAO

Healthcare Biotechnology

XOMA Royalty Corporation, formerly XOMA Corporation, is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments... see more

Add To Watchlist

Recent & Breaking News (NDAQ:XOMAO)

XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities

GlobeNewswire November 7, 2024

XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience

GlobeNewswire October 22, 2024

Zevra's MIPLYFFA(TM) (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)

GlobeNewswire September 23, 2024

XOMA Royalty Declares Quarterly Preferred Stock Dividends

GlobeNewswire September 23, 2024

XOMA Royalty to Present at Upcoming Investor Conferences in September

GlobeNewswire September 4, 2024

XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities

GlobeNewswire August 13, 2024

XOMA Declares Quarterly Preferred Stock Dividends

GlobeNewswire June 20, 2024

XOMA Receives $8.1 Million Milestone Related to Day One Biopharmaceuticals' Sale of its Priority Review Voucher

GlobeNewswire June 12, 2024

XOMA to Present at H.C. Wainwright 2nd Annual Bioconnect Investor Conference at NASDAQ

GlobeNewswire May 14, 2024

XOMA Reports First Quarter 2024 Financial Results and Highlights Recent Activities

GlobeNewswire May 9, 2024

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO(TM) (clindamycin phosphate) Vaginal Gel 2%

GlobeNewswire April 30, 2024

XOMA Earns $9 Million Milestone as FDA Grants Accelerated Approval to Day One's OJEMDATM (tovorafenib) for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG)

GlobeNewswire April 25, 2024

XOMA Corporation Announces Closing of Tender Offer

GlobeNewswire April 3, 2024

XOMA Declares Quarterly Preferred Stock Dividends

GlobeNewswire March 21, 2024

XOMA Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Kinnate Biopharma Inc.

GlobeNewswire March 19, 2024

XOMA Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent and Upcoming Events Expected to Drive Shareholder Value

GlobeNewswire March 8, 2024

XOMA to Present at Upcoming Investor Conferences in March

GlobeNewswire February 28, 2024

XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right

GlobeNewswire February 16, 2024

XOMA Expands its Commercial Royalty and Milestone Portfolio with DSUVIA® Acquisition

GlobeNewswire January 18, 2024

FDA Acceptance of Zevra's Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to LadRx

GlobeNewswire January 11, 2024